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Abstract
Amyloid precursor protein binding protein-1 (APP-BP1) binds to the carboxyl terminus of the amyloid precursor protein
(APP) and serves as the bipartite activation enzyme for the ubiquitin-like protein, NEDD8. In the present study, we explored
the physiological role of APP-BP1 in the cell cycle progression of fetal neural stem cells. Our results show that cell cycle
progression of the cells is arrested at the G1 phase by depletion of APP-BP1, which results in a marked decrease in the
proliferation of the cells. This action of APP-BP1 is antagonistically regulated by the interaction with APP. Consistent with
the evidence that APP-BP1 function is critical for cell cycle progression, the amount of APP-BP1 varies depending upon cell
cycle phase, with culminating expression at S-phase. Furthermore, our FRET experiment revealed that phosphorylation of
APP at threonine 668, known to occur during the G2/M phase, is required for the interaction between APP and APP-BP1. We
also found a moderate ubiquitous level of APP-BP1 mRNA in developing embryonic and early postnatal brains; however,
APP-BP1 expression is reduced by P12, and only low levels of APP-BP1 were found in the adult brain. In the cerebral cortex
of E16 rats, substantial expression of both APP-BP1 and APP mRNAs was observed in the ventricular zone. Collectively, these
results indicate that APP-BP1 plays an important role in the cell cycle progression of fetal neural stem cells, through the
interaction with APP, which is fostered by phopshorylation of threonine 668.
Citation: Joo Y, Ha S, Hong B-H, Kim Ja, Chang K-A, et al. (2010) Amyloid Precursor Protein Binding Protein-1 Modulates Cell Cycle Progression in Fetal Neural
Stem Cells. PLoS ONE 5(12): e14203. doi:10.1371/journal.pone.0014203
Editor: Brian Christie, University of Victoria, Canada
Received July 21, 2010; Accepted November 4, 2010; Published December 2, 2010
Copyright:  2010 Joo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Brain Research Center of the Twenty-First Century Frontier Research Program Grant and National Research Foundation
of Korea Grants 2008-314-E00179 awarded to J-H. Kim and ROI-2008-000-20275-0 awarded to H-S Kim by the Ministry of Education, Science and Technology,
Republic of Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hyisun@snu.ac.kr
Introduction
Amyloid precursor protein binding protein-1 (APP-BP1) has
been known to interact with the intracellular carboxyl (C-)
terminus of the amyloid precursor protein (APP), the precursor
protein of amyloid beta peptide (Ab), which is the main
component of neuritic plaques in Alzheimer’s disease (AD)
[1],[2],[3].
APP-BP1, like APP, is ubiquitously expressed in neural and
non-neural tissues [4]. The intracellular C-terminal domain of
APP interacts with several proteins, including the Fe65 protein
family [5], JNK interacting protein 1 [6], X11 [7], APP-BP1 [4],
and others. Although extensive research has been done to
characterize the normal physiological function of APP and its
interaction with the proteins described above, there are many
aspects that still require clarification.
APP-BP1 is localized to human chromosome 16 band q22 [4]
and acts as one component of the bipartite activating enzyme for
the ubiquitin-like small molecule, NEDD 8 [8],[9],[10]. Upon
binding to Uba3, which is homologous to the carboxyl terminus of
E1, APP-BP1 acts as an activating enzyme, thus activating
NEDD8. APP-BP1/Uba3 also interacts with the N-terminus of
the conjugating enzyme Ubc12, which is analogous to E2 in the
uniquitination pathway [9], [10], [11], [12].
Neddylation is involved in various cellular functions including
cell cycle progression [13], [14], [15]. Several targets for
neddylation exists in mammalian cells, including the cullin (Cul)
family members, a major constituent of the ubiquitin-ligase, Skp-1-
Cul-1-F box (SCF) complex [16], [17]. SCF ubiquitin ligase targets
p27, the cyclin-dependent kinase (cdk) inhibitor, for degradation
during the transition of cells from the G0/G1 phase to the S phase
of the cell cycle [18], and also regulate PDCD4, Cdc25A, Claspin,
Wee1, Emi1, cyclin E, and cyclin D1, all of which are key
substrates within the cell division cycle [19], [20].
Overexpression of APP-BP1 in primary neurons induces
apoptosis and increases DNA synthesis [21]. In addition, up-
regulated APP-BP1 expression has been observed in the lipid rafts
in the hippocampi of AD brains, when compared with age-
matched control brains [22].
In this study, we focused on the role for APP-BP1 in neural
stem cell cycle progression, and demonstrated that APP-BP1 is
critically required for cell cycle progression. This action of APP-
BP1 is antagonistically regulated by the interaction with APP.
Additionally, phosphorylation of APP at the threonine 668
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14203residue was found to be required for the interaction with APP-
BP1.
Results
APP-BP1 knockdown induced cell cycle arrest at G1
phase
To investigate whether APP-BP1 affects the cell cycle
progression of fetal neural stem cells, we first tested the knockdown
effect of siRNAs for APP-BP1 (APP-BP1 siRNA) by comparing
them with non-targeting control siRNA. We found that treatment
with the targeted siRNA for 72 h reduced the protein level of
APP-BP1 by about 50% (Figure S1A). An analysis of the cell cycle
was then performed using 10,000 cells pulled from three treatment
groups: untreated cells, non-targeting control siRNA-, or APP-BP1
siRNA-transfected fetal neural stem cells (passage 8) and HEK 293
cells, employing a FACS. After the cells were treated with either
the vehicle, non-targeting siRNA or APP-BP1 siRNA for 72 h,
cells were harvested and fixed with 70% ethanol for 1 h, and
stained with PI for 1 h. FACS was performed as described in
Materials and Methods.
We found that the cell population at G1 phase had increased in
both HEK 293 cells (data not shown) and fetal neural stem cells
(Fig. 1). The cell population at G1 phase in untreated and non-
targeting siRNA-treated fetal neural stem cells was 48.8 and
55.7%, respectively. In APP-BP1 siRNA-treated cells, the cell
population at G1 phase was 70.5% in fetal neural stem cells. The
percentage of the cell population at S phase was 17.0%, 16.2%
and 12.1% in untreated, non-targeting siRNA-treated and APP-
BP1 siRNA-treated cells, respectively. The percentage of the cell
population at the G2/M phase was 34.2%, 28.0% and 17. 4% in
untreated, non-targeting siRNA-treated and APP-BP1 siRNA-
treated cells, respectively (Fig. 1). These results demonstrated that
APP-BP1 is required for the cell cycle progression from G1 to S
phase.
APP-BP1 is required for the proliferation in fetal neural
stem cells
We next determined whether APP-BP1 knockdown affected the
proliferation of fetal neural stem cells. Bromodeoxyuridine (5-
bromo-2-deoxyuridine, BrdU) was used to examine proliferation.
BrdU can be incorporated into the newly synthesized DNA of
replicating cells during the S phase of the cell cycle, where it
substitutes for thymidine during DNA replication. The cells were
treated with 30 mM BrdU after vehicle or siRNAs treatment for
24 h. After 24 h, cells were dissociated and incubated for 10 min
before being placed on laminin coated coverslips and examined
using immunocytochemistry with an anti-BrdU antibody. We
calculated the ratio of BrdU positive cells to the total number of
cells in 5 independent experiments. A total of about 700–1100 cells
were analyzed from each experiment. We found that this ratio was
significantly decreased in APP-BP1 siRNA-transfected fetal neural
stem cells (36.9266.75%), compared to untreated cells
(64.7465.95%) (Fig. 2).
APP knockdown increased proliferation in fetal neural
stem cells
We also examined whether the knockdown of APP, the binding
partner of APP affected the proliferation of fetal neural stem cells
using BrdU staining as described above. A total of about 700–1100
cells were analyzed from each experiment. APP siRNA treatment
was shown to reduce APP protein level by about 50% (Figure
S1B). The ratio of BrdU positive cells to the total number of cells
was significantly increased in APP siRNA transfected fetal neural
stem cells (81.7466.54%), compared to untreated control cells
(57.9769.70%) (Fig. 3). We also found that the treatments with
both APP and APP-BP1 siRNAs into the cells significantly reduced
the BrdU positive cells (39.0661.39%), compared to untreated
control cells (69.5561.12%) (Fig. 4). These results suggest that
APP antagonistically regulates APP-BP1’s function in cell cycle
progression.
APP-BP1 expression varied according to cell cycle phase
Next, we investigated whether APP-BP1 expression was altered
according to the cell cycle progression. Fetal neural stem cells were
synchronized to the G1 phase by treatment with 2 mM thymidine
for 16 h, and then released from cell cycle arrest by replacing the
thymidine-containing media. Cells were harvested at 0, 2, 4, 6, 8,
10 and 12 h after cell cycle arrest through treatment with 2 mM
thymidine, and the APP-BP1 protein level was examined via
Western blotting (Fig. 5). APP-BP1 was increased at 4 h,
corresponding to the S phase in FACS measurements (data not
Figure 1. APP-BP1 knockdown arrests cell cycle at G1-phase in fetal neural stem cells. The DNA content of the siRNAs treated fetal neural
stem cells (Passage 8) was evaluated by flow cytometry with a FACScan instrument. Each group represents the status of the cell cycle for 10,000 cells.
doi:10.1371/journal.pone.0014203.g001
APP-BP1 in Cell Cycle
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that APP-BP1 was induced in the S phase and thus, may play a
role in S phase or the progression from G1 to S phase.
The expression of APP and APP-BP1 during
developmental stages was investigated
Although the expression profile of APP-BP1 during develop-
ment in Drosophila was reported previously [23], there has been no
report on the expression profile of APP–BP1 in mammals. We
investigated the mammalian expression pattern of APP-BP1 and
APP, based on our hypothesis that APP-BP1 plays a role in
accordance with APP.
A moderate level of APP-BP1 mRNA signal was ubiquitously
observed in the developing embryonic and early postnatal brains
(Fig. 6A–D). However, APP-BP1 expression appeared to be
reduced by P12 (Fig. 6D), and only a marginal signal was found in
the adult brains (Fig. 6E). Alternatively, strong APP mRNA signals
were observed in both the developing and adult brains (Fig. 6F–J).
The expression of APP was strong in the ventral region of the
spinal cord in the E16 embryo (Fig. 6G, inset). Compared with
APP, APP-BP1 expression was ubiquitously observed in the E16
spinal cord (Fig. 6B, inset). In the cerebral cortex of E16 rats,
substantial signals for both APP-BP1 (Fig. 6K) and APP (Fig. 6L)
mRNAs were observed in the ventiricular zone (VZ) where
proliferating neuroepithelial cells are enriched. The expression of
APP was stronger in the cortical plate (CP) where post-mitotic
neurons reside, whereas the expression level of APP-BP1 in the VZ
and CP was similar. On P0, strong expression of APP was
observed in the thalamus, hippocampus, and cerebellum. In the
P0 cerebellum, the APP signal was especially strong in the external
germinal layer (EGL; Figure 4N, inset) and inner granule cell layer
(IGL, Fig. 6N), whereas APP-BP1 expression was only marginal.
As opposed to APP-BP1 (Fig. 6E), strong expression of APP was
maintained in the adult brain (Fig. 6J). In particular, APP
expression was strong in the adult hippocampus and cerebellum.
These ISH signals appeared to be specific because sense probe
hybridization exhibited a markedly reduced or complete lack of
signals compared to the antisense hybridizations (Fig. 6O, P).
Molecular interaction between APP-BP1 and APP was
examined by FRET analysis
APP-BP1 has been reported to interact with the intracellular C-
terminal domain of APP [4], however, the physiological
significance of this interaction remains unclear. According to the
Figure 2. siRNA-mediated APP-BP1 knock-down significantly decreases BrdU-incorporated fetal neural stem cells. Fetal neural stem
cells were subcultured in 6-well plates, in proliferating media, and then treated the cells with 10 nM siRNAs. After 24 h, the cells were treated with
BrdU (1 mM) for 24 h. We then dissociated the neurospheres, and transferred the cells to new 6-well plates with 12 mm glass coverslips pre-coated
with laminin (20 mg/ml). The cells were cultured in the differentiation media without growth factors for 30 min and assessed with
immunocytochemistry using an anti BrdU and Cy3-secondary antibodies. DAPI (1 mM) staining shows the location of the nucleus (blue). DIC
represents differential image contrast. BrdU immunoreactive cells were calculated in five independent experiments (10 fields were evaluated per each
experiment) with respect to the ratio of BrdU stained cells to total cells. Data are expressed as mean 6 SEM values. One-way ANOVA was used to
determine statistical significance at p,0.05 by post hoc analysis via Duncan’s test. Scale bars=50 mm.
doi:10.1371/journal.pone.0014203.g002
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threonine 668. During the G2/M phase, APP phosphorylation is
maximally induced by cdc2 kinase at threonine 668 [24]. We also
confirmed that APP is phosphorylated at threonine 668 during the
G2/M phase in SHSY5Y cells (Figure S2 and S3). We
hypothesized that the interaction between APP and APP-BP1
might be regulated by APP phosphorylation at threonine 668. To
test this theory, we examined the effect of threonine 668
phosphorylation on the APP/APP-BP1 interaction using a FRET
method to compare wild-type and mutant clones: APP-BP1 cloned
in a pZsYellow- N1 vector, APP in a pAMCyan1- N1 vector, and
a point mutation APP
T668A in a p pAMCyan1- N1 vector (Fig. 7).
HEK293 cells on coverslips in 6-well plates were transiently co-
transfected with one of the following combinations: 1) pAMC-
yan1-N1 vector and pZsYellow-N1 vector, 2) pAMCyan 1- APP
and pZsYellow- APP-BP1, 3) pAMCyan1-APP
T668A and
pZsYellow-APP-BP1 (Figs. 8, 9, 10). At 24 h after transfection,
the coverslips were mounted on an Axiovert 200 inverted
microscope (Zeiss, Jena Germany). The energy transfer was
detected as an increase in donor fluorescence (AMCyan1) after
complete photobleaching of the acceptor molecules (ZsYellow).
Cells showing both AMCyan1 and ZsYellow signals were
photobleached at 514 nm (laser power 100%) to destroy the
acceptor molecules. The cells were then rescanned using 458-nm
light and an increase of the AMCyan1 signal within the
photobleached area was used as a measure of FRET. As shown
in Fig. 8, the cells co-expressing pAMCyan1 and pZsYellow
vectors only showed no change in AMCyan1 donor signal after
photobleaching of the ZsYellow signal at 514 nm. In Fig. 9,
AMCyan1 donor signal was significantly increased after complete
photobleaching of ZsYellow signal at 514 nm, indicating that
FRET is present between APP-BP1 and wild -type APP. By
contrast, FRET was not observed between pZsYellow-APP-BP1
and pAMCyan1-APP
T668A (Fig. 10). It was confirmed that the
subcellular localization of APP and APP
T668A showed no
difference, which excluded the possibility that FRET would be
affected by altered subcellular localization due to the mutation of
APP at threonine 668 (Figure S4). These results suggest that the
interaction between the two proteins is dependent upon the
APP phosphorylation at threonine 668, and that the site-specific
phopshorylation inhibits the interaction between the two
proteins.
Figure 3. siRNA-mediated APP knock-down significantly increases the proliferation of fetal neural stem cells. Fetal neural stem cells
were subcultured in 6-well plates, in proliferating media, and then treated the cells with 10 nM siRNAs. After 24 h, the cells were treated with BrdU
(1 mM) for 24 h. We then dissociated the neurospheres, and transferred the cells to new 6-well plates with 12 mm glass coverslips pre-coated with
laminin (20 mg/ml). The cells were cultured in the differentiation media without growth factors for 30 min and assessed with immunocytochemistry
using an anti BrdU and Cy3-secondary antibodies. DAPI (1 mM) staining shows the location of the nucleus (blue). DIC represents differential image
contrast. BrdU immunoreactive cells were calculated in five independent experiments (10 fields were evaluated per each experiment) with respect to
the ratio of BrdU stained cells to total cells. Data are expressed as mean 6 SEM values. One-way ANOVA was used to determine statistical significance
at p,0.05 by post hoc analysis via Duncan’s test. Scale bars=50 mm.
doi:10.1371/journal.pone.0014203.g003
APP-BP1 in Cell Cycle
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Since APP-BP1 was first identified as a protein that interacts
with APP [4], numerous studies have investigated its functions as
well as its possible pathological roles in AD [22]. APP-BP1 has
been reported to be one component of bipartite enzyme complex,
together with hUba3 and to be involved in SCF complex
activation [8],[9],[11]. Exogenous expression of APP-BP1 in ts41
cells containing the phenotype which leads to successive S phases
of the cell cycle without intervening G(2), M, and G(1), was shown
to drive the cell cycle through the S-M checkpoint and this
function requires both hUba3 and hUbc12 [25]. Overexpression
of APP-BP1 causes DNA synthesis and apoptosis in primary
neurons [22],[25]. In the mean time, APP-BP1 downregulates
Ab1–42 production by interacting with PS1 under physiological
conditions in primary neurons [26].
In this study, we investigated the normal physiological role for
APP-BP1 in the cell cycle progression of fetal neural stem cells.
APP-BP1 knockdown by siRNA treatment was found to inhibit the
cell cycle transition into S phase, resulting in G1 phase arrest (as
shown in Fig. 1). We also confirmed that BrdU-incorporated cells
were significantly decreased in APP-BP1 siRNA-transfected fetal
neural stem cells (Fig. 2), indicating that proliferation was reduced
in APP-BP1 siRNA-treated fetal neural stem cells. Interestingly,
APP knockdown was found to increase the proliferation of fetal
neural stem cells (Fig. 3). These results strongly suggest that APP-
BP1 modulates the cell cycle progression of fetal neural stem cells
and that APP antagonistically regulates the function of APP-BP1
in cell cycle progression from G1 to S Phase.
We next investigated the changes in APP-BP1 protein levels
during different cell cycle phases, and we found that APP-BP1
levels, measured through Western blotting, were highly increased
in the S phase of fetal neural stem cells (Fig. 5). These results
indicate that APP-BP1 is required for the transition from G1 to S
phase, and that its expression is increased at S phase in fetal neural
stem cells.
Figure 4. siRNA-mediated knock-down of APP-BP1 and APP significantly down-regulates the proliferation of fetal neural stem cells.
Fetal neural stem cells were subcultured in 6-well plates, in proliferating media, and then treated the cells with 10 nM siRNAs. After 24 h, the cells
were treated with BrdU (1 mM) for 24 h. We then dissociated the neurospheres, and transferred the cells to new 6-well plates with 12 mm glass
coverslips pre-coated with laminin (20 mg/ml). The cells were cultured in the differentiation media without growth factors for 30 min and assessed
with immunocytochemistry using an anti BrdU and Cy3-secondary antibodies. DAPI (1 mM) staining shows the location of the nucleus (blue). DIC
represents differential image contrast. BrdU immunoreactive cells were calculated in five independent experiments (10 fields were evaluated per each
experiment) with respect to the ratio of BrdU stained cells to total cells. Data are expressed as mean 6 SEM values. One-way ANOVA was used to
determine statistical significance at p,0.05 by post hoc analysis via Duncan’s test. Scale bars=50 mm.
doi:10.1371/journal.pone.0014203.g004
APP-BP1 in Cell Cycle
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been reported to interact antagonistically with APP-like protein
(APPL) during Drosophila development. These reports showed that
a null mutation of dAPP-BP1 blocks the NEDD8 conjugation
pathway and causes apoptosis in imaginal disc cells. Furthermore,
APPL overexpression inhibits the NEDD 8 conjugation pathway,
disrupts the normal bristle pattern in the fly thorax, and induces
apoptosis in wing imaginal discs [26].
In the present study, we used an ISH method to examine the
expression patterns of both APP-BP1 and APP during rat
developmental stages. While immunohistochemical analyses of
APP expression during various developmental stages in rats have
been reported [27], ours is the first report of the expression profile
of APP-BP1 during developmental stages in mammals.
We found a moderate, ubiquitous level of APP-BP1 mRNA
signal in developing embryonic and early postnatal brains (Fig. 6A–
D), but APP-BP1 expression appeared to be reduced by P12
(Fig. 6D), and only a marginal signal of APP-BP1 was found in the
adult brain (Fig. 6E). We were especially interested in whether
APP-BP1 and APP colocalize in VZ, where neural precursor cells
proliferate. In the cerebral cortex of E16 rat, substantial signals for
both APP-BP1 (Fig. 6K) and APP (Fig. 6L) mRNAs were observed
in VZ.
It has been reported that the last 31 C-terminal amino acids of
APP are critical for the interaction with APP-BP1 [22]. APP
contains several putative phosphorylation sites within its cytoplas-
mic domain. Among them, threonine 668 was reported to be
phosphorylated in a cell cycle- dependent manner during the G2/
M phase [24]. Here, we tested whether the interaction between
APP-BP1 and APP was affected by phosphorylation at threonine
668 by FRET assay. We found that the interaction of APP-BP1
and APP is mediated by phosphorylation of APP at threonine 668.
When APP-BP1 in the pZsYellow vector and APP
T668A in the
pAMCyan1 vector were co-transfected, no FRET was observed
(Fig. 10), and when APP-BP1 in the pZsYellow vector was co-
transfected with wild-type APP in the pAMCyan1 vector,
AMCyan1 fluorescence was significantly increased after photo-
bleaching at 514 nm (Fig. 9). These results show that the
phosphorylation of APP at threonine 668 is required for the
interaction with APP-BP1.
In the present study, we found that APP-BP1 plays a role in the
cell cycle progression of fetal neural stem cells. Furthermore this
effect appears to be antagonistically regulated by APP. In addition,
we found a moderate ubiquitous level of APP-BP1 mRNA in
developing embryonic and early postnatal brains; however, APP-
BP1 expression is reduced by P12, and only low levels of APP-BP1
were found in the adult brain. In the cerebral cortex of E16 rats,
substantial expression of both APP-BP1 and APP mRNAs was
observed in the ventricular zone.
Materials and Methods
Reagents and antibodies
Anti-APP-BP1 and anti-GAPDH (FL-335) antibodies were
obtained from Santa Cruz Biotechnology (CA, USA); Anti-APP
(6E10) antibody, from Chemicon (CA, USA). The source of
siRNA for APP-BP1 (SMARTpoolH reagent) was Dharmacon
(CO, USA). pAM Cyan1-N1 and pZsYellow- N1 vectors were
obtained from Clontech (CA, USA).
Fetal neural stem cell culture
Fetal neural stem cell culture was performed as previously
described [28]. C57BL6 mouse fetal cortex was dissected at
gestation days 13, TP13 (timed pregnant 13; Japan SLC. Inc,
Haruno Breeding branch). Cells were isolated by mechanical
dissociation in MEM (minimum essential medium) supplemented
with 1M HEPES, 1% penicillin/streptomycin (pH 7.2), and 10
7
cells were plated in T75 flask and the generation of neural sphere
Figure 5. APP-BP1 expression varied according to cell cycle phase. Fetal neural stem cells were synchronized to G1 phase by treatment with
2 mM thymidine for 16 h, and then released from cell cycle arrest by replacing the thymidine-containing media. Cells were harvested at 0, 2, 4, 6, 8,
10 and 12 h, and APP-BP1 protein levels were examined by Western blotting. The blot is representative of three independent experiments. The
protein level of GAPDH was examined as a loading control.
doi:10.1371/journal.pone.0014203.g005
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mRNA was detected by ISH at E14 (A, F), E16 (B, G) embryos and P0 (C, H), P12 (D, I), and in adult (E, J) brains. Insets in B and G show a large
magnification view of spinal cord. (K–N): Emersion-developed black silver grains of APP-BP (K, M) and APP (L, N) mRNA signal showed distribution in
the E16 cerebral cortex (K, L) and P0 cerebellum (M, N). Insets in K and L show large magnification view of CP (upper insets) and VZ (lower insets),
and the insets in M and N shows enlarged views of EGL. (O, P): Adult brain sections were hybridized with sense probes for APP-BP (O) or APP (P).
Experiments were duplicated, and typical images are shown. Abbreviations: Ctx, cerebral cortex; Cbll, cerebellum; Sc, spinal cord; Ht, heart; Li, liver;
Kd, kidney; Str, striatum; Th, thalamus; Hip, hippocampus; Ob, olfactory bulb; v, ventral spinal cord; d, dorsal spinal cord; CP, cortical plate; IZ,
intermediate zone; VZ, ventricular zone; EGL, external germinal layer; PCL, Purkinje cell layer; IGL, inner granule cell layer; MZ/WM, marginal zone/
white matter.
doi:10.1371/journal.pone.0014203.g006
Figure 7. A list of DNA constructs used in FRET experiments. A list of DNA constructs used in FRET study (Figures 8–10) was shown.
doi:10.1371/journal.pone.0014203.g007
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described [29]. Briefly, fetal neural stem cells were aggregated to a
neurosphere, whereupon, cells were allowed to proliferate in the
proliferating media, Dulbecco’s modified Eagle’s medium/F-12
(1 : 1) (Gibco, Grand Island, NY, USA) medium supplemented
with 2 mmol/L L-glutamine (Gibco), 0.6% glucose, 5 mmol/L
HEPES, 25 mg/mL insulin, 100 mg/mL apo-transferrin,
30 nmol/L sodium selenite, 100 nmol/L putresine, and
20 nmol/L progesterone (all supplements purchased from Sigma,
MO, USA) with 10 ng/mL recombinant basic fibroblast growth
factor (bFGF; Roche, Mannheim, Germany) and 20 ng/mL
epidermal growth factor (EGF; BD sciences, MA, USA) for 4
days. For BrdU incorporation assessment, we dissociated the
neurospheres and subcultured fetal neural stem cells (5610
5 cells/
well) in 6-well plates, in proliferating media, and then treated the
cells with 10 nM siRNAs. After 24 h, the cells were treated with
BrdU (1 mM) for 24 h. Then we transferred the cells to new 6-well
plates that contained 12 mm glass coverslips (Marienfeld, Lauda-
Konlgshofen, Germany) pre-coated with laminin (Roche, Mann-
heim, Germany) at the concentration of 20 mg/ml. The cells were
cultured in the differentiation media without growth factors (EGF
and bFGF) for 30 min and assessed with immunocytochemistry
using an anti BrdU-antibody.
Immunocytochemistry for BrdU staining
Cells were fixed in 4% paraformaldehyde for 20 min at room
temperature. They were washed in PBS containing 0.3% Triton
X-100 for 5 min, 3 times for permeabilization and treated 1N HCl
for 10 min on ice and then 2N HCl for 10 min on room
temperature for DNA denaturation. After three times washing in
Figure 8. Molecular interaction between pZsYellow vector and pAMCyan1 vector was examined by FRET. HEK 293 cells on coverlips in
6-well plates were transiently co-transfected with pZsYellow vector and pAMCyan1 vector. Figures in the left panel show representative results from
the seven independent experiments. The right upper panel shows a representative graph indicating the time-lapse fluorescence changes in the
region of interest (ROI). Green line: AMCyan1 fluorescence; gray: ZsYellow throughout the progression of successive bleaching marked as vertical
green bars. In the right lower panel, relative fluorescence intensity is denoted after standardization of intensities before and after photobleaching of
ZsYellow at 514 nm. *p,0.05 versus fluorescence intensity before photobleaching of ZsYellow at 514 nm (by Student’s t-test). Scale bars=50 mm.
doi:10.1371/journal.pone.0014203.g008
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for 12 min at room temperature. After three washes in
perrmeabilization buffer, they were blocked by 5% normal goat
serum in permiabilization buffer for 1 h at room temperature. And
then cells were incubated with BrdU primary antibody (final
concentration: 5 mg/ml) diluted in permeabilization buffer for
overnight at 4uC. After three washes, primary antibodies were
revealed by incubating the cells for 1 h with Cy3 conjugated
secondary antibody at a dilution ratio of 1:300 (Jackson
ImmunoResearch, PA, USA). After three washes in PBS, cells
were mounted on microscope slides in mounting medium (DAKO,
CA, USA) that included DAPI (1 mM) for nuclear staining. Cells
were then observed under a Confocal microscope (LSM 510,
Zeiss, Germany). For BrdU staining experiment, totally fifteen
pregnant mice were used for culturing fetal neural stem cells. Five
independent experiments were performed for each experiment.
Figure 9. Molecular interaction between APP-BP1 and APP was examined by FRET. HEK 293 cells on coverlips in 6-well plates were
transiently co-transfected with pZsYellow-APP-BP1 and pAMCyan1-APP. Figures in the left panel show representative results from the seven
independent experiments. The right upper panel shows a representative graph indicating the time-lapse fluorescence changes in the region of
interest (ROI). Green line: AMCyan1 fluorescence; gray: ZsYellow throughout the progression of successive bleaching marked as vertical green bars.I n
the right lower panel, relative fluorescence intensity is denoted after standardization of intensities before and after photobleaching of ZsYellowa t
514 nm. *p,0.05 versus fluorescence intensity before photobleaching of ZsYellow at 514 nm (by Student’s t-test). Scale bars=50 mm.
doi:10.1371/journal.pone.0014203.g009
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Human APP-BP1 cDNA included in the pcDNA3 vector was
kindly provided by Dr. Rachael L. Neve at Harvard Medical
School. The constructs of pAM Cyan 1-APP and pZsYellow-APP-
BP1 were generated by PCR from human APP-BP1 in the
pcDNA3 vector and human APP in the pCB6 vector, respectively.
To construct the T668A post mutation of APP, we used a
QuickChange Site-Directed Mutagenesis Kit (Stratagene, CA,
USA).
Cell cycle analysis
Fetal neural stem cells were synchronized to G1 phase by
treatment with 2 mM thymidine for 16 h, and then released from
cell cycle arrest by replacing the non thymidine-containing media.
Cells were harvested at 0, 2, 4, 6, 8, 10 and 12 h, and APP-BP1
protein levels and DNA contents were examined by Western
blotting and flow cytometry, respectively. Harvested cells were
washed three times with phosphate-buffered saline (PBS), fixed in
70% ethanol, stained with propidium iodide (PI, 25 mg/mL)
Figure 10. Molecular interaction between APP-BP1 and APP
T668A was examined by FRET. HEK 293 cells on coverlips in 6-well plates were
transiently co-transfected with pZsYellow-APP-BP1 and pAMCyan1-APP
T668A. Figures in the left panel show representative results from the seven
independent experiments. The right upper panel shows a representative graph indicating the time-lapse fluorescence changes in the region of
interest (ROI). Green line: AMCyan1 fluorescence; gray: ZsYellow throughout the progression of successive bleaching marked as vertical green bars.I n
the right lower panel, relative fluorescence intensity is denoted after standardization of intensities before and after photobleaching of ZsYellowa t
514 nm. *p,0.05 versus fluorescence intensity before photobleaching of ZsYellow at 514 nm (by Student’s t-test). Scale bars=50 mm.
doi:10.1371/journal.pone.0014203.g010
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mL) (Roche Applied Science, USA). Cellular DNA content was
then evaluated by flow cytometry with a fluorescence activated
sorting (FACS) Scan instrument (BD Biosciences).
Western blotting
Proteins were resolved in sodium dodecyl sulfate (SDS)
polyacrylamide gels, electrophoresed with 30–50 mg protein/lane,
and transferred onto a nitrocellulose membrane (GE Healthcare
AB, Sweden). The protein blot was confirmed with anti-APP-BP1
and anti-GAPDH antibodies at final concentrations of 0.2 and
0.2 mg/ml, respectively, and detected with a horseradish perox-
idase-conjugated secondary antibody (GE Healthcare AB, Swe-
den) at a dilution ratio of 1:2000. Immunoreactive bands were
visualized with an enhanced chemiluminescence system (ECL; GE
Healthcare AB, Sweden).
Fluorescence resonance energy transfer (FRET)
FRET measurements were observed using a Zeiss LSM 510
confocal microscope mounted on Zeiss Axiovert 200 inverted
microscope. FRET was measured by employing a method
developed for laser scanning confocal microscopy that usesa an
argon laser to excite Cyan1 or ZsYellow. HEK293 cells on 6 well
plates were co-transfected with one of the following combinations:
1) pAMCyan1-N1 vector and pZsYellow-N1 vector, 2) pAMCyan
1- APP and pZsYellow- APP-BP1, 3) pAMCyan1-APP
T668A and
pZsYellow-APP-BP1 using Fugene 6 (Roche Molecular Biochem-
icals, Germany). 24 h after transfection, the coverslips were
mounted on the Axiovert 200 inverted microscope (Zeiss, Jena
Germany). An initial scan was obtained at low energy using the
458 nm line of an argon laser to record the AMCyan1 signal. A
second scan was performed with the 568 nm line, and the co-
localization of cells was recorded. Cells were then photobleached
with intense 514 nm light (laser power 100%) to destroy the
acceptor molecules. Energy transfer was detected as an increase in
donor fluorescence (AMCyan1) after complete photobleaching of
the acceptor molecules (ZsYellow) at 514 nm. The amount of
energy transfer was calculated as the percent increase in donor
fluorescence after acceptor photobleaching. An increase of the
ZsYellow signal within the photobleached area was used as a
measure of the amount of FRET present.
In situ hybridization
In situ hybridization (ISH) was carried out as previously
described [30]. Embryos and postnatal brains from rats were
prepared at different developmental stages. Frozen sections
(12 mm) were cut sagitally (embryo) or horizontally (postnatal
brains), post-fixed with 4% paraformaldehyde, treated with 0.25%
acetic anhydride in 0.1 M triethanolamine/0.9% NaCl, and
dehydrated in ethanol/chloroform. The probes used in this study
were generated against the 234–723 nucleotide sequences of APP
(GenBank No, NM 019288), and the 299–815 nucleotide
sequences of APP-BP1 (GenBank No, NM032072) in the presence
of a-[35S] UTP (1000–1500 Ci/mmol, GE Healthcare AB,
Sweden). Sections were hybridized overnight at 53uC with the
labeled probe. The following day, the sections were treated with
RNase A (20 mg/mL, Roche Germany) for 30 min at 25uC, and
washed in a series of SSC baths: 60 min in 26 SSC at 50uC,
60 min in 0.26SSC at 55uC, and 60 min in 0.26SSC at 60uC.
The sections were then rinsed briefly in a graded series of ethanols
baths containing 0.3 M ammonium acetate. Finally, sections were
then exposed to b-max film (GE Healthcare AB, Sweden) for 6
days. To examine cell-level distribution of ISH signals, some slides
were dipped into Kodak NTB2 photoemulsions, exposed,
developed, lightly counterstained with cresyl violet, and cover-
slipped. Experiments were duplicated.
Statistical Analysis
Data are expressed as mean 6 SEM values. One-way ANOVA
and Student’s t-tests (SPSS, Chicago, IL) were used for
determining statistical significance. Results were considered
statistically significantly for p,0.05.
Supporting Information
Figure S1 The effect of siRNA for APP was detected by Western
blotting. (A) After the treatment of fetal neural stem cells with
10 nM of non-targeting and APP-BP1 siRNAs for 72 h, APP-BP1
protein level was examined by Western blotting. Densitometrical
analysis was also performed (* p,0.05). (B) After treatment of fetal
neural stem cells with 10 nM of non-targeting and APP siRNAs
for 72 h, APP protein level was examined by Western blotting.
Found at: doi:10.1371/journal.pone.0014203.s001 (1.44 MB
TIF)
Figure S2 Phosphorylation of APP at threonine 668 was
examined according to cell cycle phases SH-SY5Y cells were
synchronized to the G1 phase by treatment with 2 mM thymidine
for 16 h, and then released from cell cycle arrest by replacing the
thymidine-containing media. Cells were harvested at 0, 2, 4, 6, 8,
10 and 12 h and the protein level of APP phosphorylated at
threonine 668 was examined by Western blotting.
Found at: doi:10.1371/journal.pone.0014203.s002 (0.10 MB TIF)
Figure S3 Cell cycle analysis of SH-SY5Y cells following cell
cycle synchronization by thymidine treatment SH-SY5Y cells were
synchronized to the G1 phase by treatment with 2 mM thymidine
for 16 h, and then released from cell cycle arrest by replacing the
thymidine-containing media. SH-SY5Y cells were synchronized to
the G1 phase by treatment with 2 mM thymidine for 16 h, and
then released from cell cycle arrest by replacing the thymidine-
containing media. Cells were harvested at 0, 2, 4, 6, 8, 10 and 12 h
and cell cycle was analysed by FACS.
Found at: doi:10.1371/journal.pone.0014203.s003 (0.16 MB TIF)
Figure S4 Confirmation of subcellular localization of APP and
APPT668A. HEK 293 cells on coverlips in 6-well plates were
transiently transfected with pAMCyan1-APP or APPT668A. 24 h
after transfection, the subcellular localization was examined using
Zeiss LSM 510 confocal microscope. Scale bars=50 mm.
Representative images were shown.
Found at: doi:10.1371/journal.pone.0014203.s004 (0.25 MB
TIF)
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